About nektar therapeutics - NKTR
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
NKTR At a Glance
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, California 94158
| Phone | 1-415-482-5300 | Revenue | 55.23M | |
| Industry | Pharmaceuticals: Major | Net Income | -164,076,000.00 | |
| Sector | Health Technology | Employees | 63 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NKTR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.915 |
| Price to Book Ratio | 9.591 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.62 |
| Enterprise Value to Sales | 11.161 |
| Total Debt to Enterprise Value | 0.242 |
NKTR Efficiency
| Revenue/Employee | 876,698.413 |
| Income Per Employee | -2,604,380.952 |
| Receivables Turnover | 31.047 |
| Total Asset Turnover | 0.189 |
NKTR Liquidity
| Current Ratio | 4.974 |
| Quick Ratio | 4.974 |
| Cash Ratio | 4.59 |
NKTR Profitability
| Gross Margin | 98.142 |
| Operating Margin | -243.466 |
| Pretax Margin | -281.516 |
| Net Margin | -297.067 |
| Return on Assets | -56.166 |
| Return on Equity | -217.941 |
| Return on Total Capital | -68.726 |
| Return on Invested Capital | -72.367 |
NKTR Capital Structure
| Total Debt to Total Equity | 165.763 |
| Total Debt to Total Capital | 62.372 |
| Total Debt to Total Assets | 53.104 |
| Long-Term Debt to Equity | 142.948 |
| Long-Term Debt to Total Capital | 53.788 |